4//SEC Filing
Fitzgerald Meghan 4
Accession 0001140361-25-034932
CIK 0001635088other
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 9:00 PM ET
Size
9.1 KB
Accession
0001140361-25-034932
Insider Transaction Report
Form 4
Fitzgerald Meghan
Director
Transactions
- Other
Common Shares
2025-09-10$13.77/sh−937$12,902→ 42,963 total - Award
Common Shares
2025-09-10+14,524→ 43,900 total - Award
Stock Option (Right to Buy)
2025-09-10+33,726→ 33,726 totalExercise: $13.77Exp: 2035-09-09→ Common Shares (33,726 underlying)
Footnotes (3)
- [F1]Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.
- [F2]Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.
- [F3]Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.
Documents
Issuer
Roivant Sciences Ltd.
CIK 0001635088
Entity typeother
Related Parties
1- filerCIK 0001349297
Filing Metadata
- Form type
- 4
- Filed
- Sep 11, 8:00 PM ET
- Accepted
- Sep 12, 9:00 PM ET
- Size
- 9.1 KB